Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;12(3):563-70.
doi: 10.1111/j.1600-6143.2011.03926.x. Epub 2012 Feb 2.

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

M Mengel  1 , B Sis, M Haas, R B Colvin, P F Halloran, L C Racusen, K Solez, L Cendales, A J Demetris, C B Drachenberg, C F Farver, E R Rodriguez, W D Wallace, D Glotz; Banff meeting report writing committee
Affiliations

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

M Mengel et al. Am J Transplant. 2012 Mar.

Abstract

The 11th Banff meeting was held in Paris, France, from June 5 to 10, 2011, with a focus on refining diagnostic criteria for antibody-mediated rejection (ABMR). The major outcome was the acknowledgment of C4d-negative ABMR in kidney transplants. Diagnostic criteria for ABMR have also been revisited in other types of transplants. It was recognized that ABMR is associated with heterogeneous phenotypes even within the same type of transplant. This highlights the necessity of further refining the respective diagnostic criteria, and is of particular significance for the design of randomized clinical trials. A reliable phenotyping will allow for definition of robust end-points. To address this unmet need and to allow for an evidence-based refinement of the Banff classification, Banff Working Groups presented multicenter data regarding the reproducibility of features relevant to the diagnosis of ABMR. However, the consensus was that more data are necessary and further Banff Working Group activities were initiated. A new Banff working group was created to define diagnostic criteria for ABMR in kidneys independent of C4d. Results are expected to be presented at the 12th Banff meeting to be held in 2013 in Brazil. No change to the Banff classification occurred in 2011.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Michael Mengel and Banu Sis received a research grant from Astellas Canada in support for the Banff Working Group activities. Michael Mengel is a consultant to Novartis Canada. Denis Glotz received honoraria/speaker’s fees from Roche, Novartis, Pfizer, Genzyme, Alexion, ORS, CSL Behring. None of the other authors has any conflicts of interest to disclose as described by the American Journal of Transplantation.

References

    1. Gloor JM, Degoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplant. 2004;78:221–227. - PubMed
    1. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21:1398–1406. - PMC - PubMed
    1. Lefaucheur C, Antoine C, Suberbielle C, Glotz D. Mastering the risk of HLA antibodies in kidney transplantation: An algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant. 2011;11:1592–1598. - PubMed
    1. Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI. Antibodies to HLA-E in nonalloimmunized males: Pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol. 2010;185:1935–1948. - PubMed
    1. Shapiro R, Lunz J, Zeevi A, et al. 1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection. Clin Transpl. 2010:405–407. - PubMed

Publication types